Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's ChemGenex Reaches Agreement With U.S. FDA To Re-file Omapro NDA For Third-Line CML Treatment

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - The chief executive officer of Melbourne-headquartered ChemGenex told investors and analysts July 14 that the company has reached agreement with U.S. FDA for a regulatory pathway forward of its Omapro (omacetaxine) new drug application for third-line treatment of chronic myeloid leukemia for patients who have failed multiple tyrosine kinase inhibitors

You may also be interested in...



Cephalon, A Target Itself, To Acquire Remainder Of Australian ChemGenex

Cephalon Inc. announced March 29 that it has struck an agreement with the Australia-based biopharma ChemGenex Pharmaceuticals Ltd. to pay A$159 million ($US $163 million) for the piece of the company it doesn't already own

Cephalon, A Target Itself, To Acquire Remainder Of Australian ChemGenex

Cephalon Inc. announced March 29 that it has struck an agreement with the Australia-based biopharma ChemGenex Pharmaceuticals Ltd. to pay A$159 million ($US $163 million) for the piece of the company it doesn't already own

FDA will let ChemGenex file Omapro in third-line CML with no mutation test required

FDA has agreed to let Australian biopharma ChemGenex seek approval for its oncology drug Omapro (omacetaxine) as a third-line therapy in chronic myeloid leukemia without a requirement for genetic testing. The agency issued a "complete response" in April on a second-line application, asking for a companion diagnostic test to select for patients with the Bcr-Abl T3151 mutation (1"The Pink Sheet" DAILY, April 12, 2010). Patients in the third-line setting are identified by their resistance to therapies rather than individual mutation status, CEO Greg Collier told analysts during a July 14 call. Based on discussions with the agency, the company will submit pooled data from two pivotal studies showing efficacy in patients who have failed prior treatment with two or more currently approved tyrosine kinase inhibitors. ChemGenex expects to file the NDA by the end of the year, while it continues to work with the agency to gain approval of the test that can move the second-line application forward. The third-line indication means a much larger patient population and commercial opportunity in the U.S., where there are no approved therapies in that setting, Collier said (2PharmAsia News, July 14, 2010). A European marketing application in the second-line setting is on track, with a potential approval in the first quarter of 2011

Related Content

UsernamePublicRestriction

Register

SC075334

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel